🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ray Dalio’s PCVX Holdings & Trades

First Buy
Q3 2025
Duration Held
4 Quarters
Largest Add
Q2 2026
+37,314 Shares
Current Position
50,217 Shares
$2.92 M Value

Ray Dalio's PCVX Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 50,217 shares of Vaxcyte, Inc. (PCVX) worth $2.92 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 4 quarters.

Based on 13F filings, Ray Dalio has maintained this position in PCVX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 37,314 shares. Largest reduction occurred in Q4 2025, reducing 11,855 shares.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Vaxcyte (PCVX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Vaxcyte (PCVX) Trades by Ray Dalio

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +37,314 Add 289.19% 50,217 $58.13
Q1 2026 +12,903 New Buy 12,903 $58.11
Q4 2025 -11,855 Sold Out 0 $0.00
Q3 2025 +11,855 New Buy 11,855 $36.02

Ray Dalio's Vaxcyte Investment FAQs

Ray Dalio first purchased Vaxcyte, Inc. (PCVX) in Q3 2025, acquiring 11,855 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Vaxcyte, Inc. (PCVX) for 4 quarters since Q3 2025.

Ray Dalio's largest addition to Vaxcyte, Inc. (PCVX) was in Q2 2026, adding 50,217 shares worth $2.92 M.

According to the latest 13F filing for Q2 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 50,217 shares of Vaxcyte, Inc. (PCVX), valued at approximately $2.92 M.

As of the Q2 2026 filing, Vaxcyte, Inc. (PCVX) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.

Ray Dalio's peak holding in Vaxcyte, Inc. (PCVX) was 50,217 shares, as reported at the end of Q2 2026.